Ascendis Pharma GAAP EPS of Euro0.55 beats by Euro4.67, revenue of Euro247.5M
Source: SeekingAlpha
2026-02-11 16:04:55 ET
More on Ascendis Pharma
- Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets
- Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
- Ascendis Pharma Q4 2025 Earnings Preview
- Ascendis Pharma rises amid takeover speculation
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma GAAP EPS of €0.55 beats by €4.67, revenue of €247.5M
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
-4.42% G/L:
$230.9284 Last:
382,909 Volume:
$240 Open:
ASND Latest News
March 02, 2026 08:43:00 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
February 27, 2026 05:57:16 pm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
